GlassScriptPhysician profile
Hans D Reisinger
NPI 1679973044
$1,977.26
in general payments reported to CMS, 2019-2025
24 companies · $632 in 2025
The $632 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $185 · 2022: $122 · 2023: $424 · 2024: $615 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,670.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $535.87 | 2023-2025 | |
| Novo Nordisk INC | $238.59 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Biotech, INC. | $173.81 | 2025 | Tremfya |
| Pfizer INC. | $167.31 | 2021-2024 | |
| Lilly USA, LLC | $152.13 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Phathom Pharmaceuticals, INC. | $126.05 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $97.98 | 2022-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $65.32 | 2023-2025 | Freestyle Libre 3 |
| Ardelyx, INC. | $61.82 | 2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $43.08 | 2023-2024 | Breztri, Farxiga, Airsupra |
| Dexcom, INC. | $39.76 | 2023-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $38.75 | 2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $38.36 | 2024-2025 | Camzyos |
| Biohaven Pharmaceutical Holding Company LTD. | $26.16 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $20.17 | 2025 | Dupixent |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $19.86 | 2025 | Entyvio |
| Novartis Pharmaceuticals Corporation | $18.88 | 2021 | |
| Apria Healthcare LLC | $18.35 | 2021 | |
| Merck Sharp & Dohme LLC | $17.53 | 2024 | Vaxneuvance, Gardasil, Vaxelis |
| Aimmune Therapeutics, INC. | $17.53 | 2025 | Zenpep |
| Bayer Healthcare Pharmaceuticals INC. | $16.91 | 2022 | |
| Eisai INC. | $15.56 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.95 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.53 | 2025 | Relistor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hans Reisinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.